1Department of Dermatology, North Staffordshire Hospital, Stoke-on Trent, UK. salim@doctors.org.uk
Interleukin-2 (IL-2) drives psoriasis by activating T-cells. New therapies targeting IL-2 production or action offer promising treatments for this inflammatory skin condition.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: